KNSA · Kiniksa Pharmaceuticals International
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a weekly close below $80
Note written ·
In the portfolio Since : +0.9% from the average price paid for its shares, 0.2 percentage points ahead of the S&P 500 from the minute it was bought. See the portfolio.
Why it was bought
Bought 10 November 2026, in the portfolio's opening purchases. The fact behind it, dated 27 October 2026: Q3 2026 results: ARCALYST net revenue $286.0 million (+58%), 2026 guide raised a third time to $1.045–1.050 billion.
Price against the kill line
20.4% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a weekly close below $80.00, on record since 11 November 2026; only a weekly close settles it. The shares are up 21.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A weekly close below $80, under the 50-day moving average, which would erase most of the gain since the 27 October 2026 report. Fourth-quarter 2026 ARCALYST revenue below the implied $301 million floor, or first 2027 guidance below about $1.30 billion, would also break the case.
The portfolio's case
ARCALYST is compounding above 50% with about 23% of roughly 14,000 multiple-recurrence pericarditis patients treated and therapy lasting about three years. The 2026 guide implies Q4 revenue of $301–306 million, a sequential gain of a third to a half of Q3's, so a beat and a 2027 guide above about $1.30 billion look more likely than the price near the $100.57 consensus target assumes.
The portfolio sells if one of these comes true
- First 2027 ARCALYST net revenue guidance below about $1.30 billion, or Q4 2026 revenue below the implied $301 million floor.
- Penetration of the roughly 14,000 multiple-recurrence patients stalls near 23–25% for two quarters, or gross-to-net deteriorates materially from 8.4% (full-year 2025).
- KPL-387 PASTORALE data slip beyond 2H27 or show a safety or efficacy problem, or a competitor shortens IL-1 therapy duration.
It can also sell when that day's research finds the stock fully priced, for a clearly better use of the money, to limit risk in the portfolio, on the weekly review's plan, when a cash takeover pays the shares out or at the end set for a shorter trade when it was bought. A close through the kill line (on a weekly line, a weekly close) means the note's call is wrong: the note is re-read, and the portfolio reads the new note at its next decision. The price alone never sells.
Catalyst
The business · as of
Kiniksa Pharmaceuticals sells ARCALYST, an injectable IL-1 blocker licensed from Regeneron, to treat recurrent pericarditis; it earns money on net product sales and shares the profits with Regeneron. Revenue was $286 million in the quarter to 30 September 2026 (10-Q filed 27 October 2026).
What is changing, and what follows · as of
- What is changing now
- On 27 October 2026 Kiniksa raised its 2026 ARCALYST net revenue guidance to $1.045–1.050 billion from $980–995 million, its third raise of the year, after third-quarter revenue of $286.0 million.
- What follows for the company
- The operating margin rose to 19.0% in the third quarter from 13.3% a year earlier; free cash flow was $197 million over four quarters and cash $569 million with no debt (10-Q, 27 October 2026).
- What follows for its customers, suppliers and competitors
- Licensor Regeneron (REGN) gains through its ARCALYST profit share; Cardiol Therapeutics (CRDL), testing CardiolRx in recurrent pericarditis, faces a larger entrenched IL-1 incumbent.
What the price assumes · as of
At the 13 November 2026 close (filed figures to 27 October 2026) the shares trade at 74.7 times earnings, 8.0 times sales and 58.3 times operating profit, for an enterprise value of $7,612 million with no debt reported; that holds only if revenue keeps growing near the 58.1% of the latest filed quarter while the operating margin keeps widening from 19.0%.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 27 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 286
- Revenue, change on a year (%)
- +58.1
- Gross margin (%)
- 90.3
- Operating margin (%)
- 19.0
- Free cash flow, four quarters ($M)
- 197
- Net cash, cash less debt ($M)
- 569
- Price to earnings (×)
- 74.7
- Enterprise value to sales (×)
- 8.0
All filed numbers
What Kiniksa Pharmaceuticals International reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 286 | +58.1 | 90.3 | 19.0 |
| first filed | 244 | +55.4 | 90.3 | 11.2 |
| first filed | 214 | +55.5 | 90.3 | 13.7 |
| first filed | 202 | +65.0 | 89.6 | 9.8 |
| first filed | 181 | +61.2 | 88.8 | 13.3 |
| first filed | 157 | +44.3 | 88.1 | 12.9 |
| Pre-tax income ($M) | 59.1 |
| Net income ($M) four quarters: 110 | 47.3 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +6.1 |
| Operating cash flow ($M) | 199 |
| Capital spending ($M) | 1.6 |
| Free cash flow ($M) | 197 |
| Cash and short-term investments ($M) | 569 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 569 |
| Deferred revenue ($M) 0.0% on a year | 31.8 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 30.8 |
| Inventory ($M) | 108 |
| Shareholders' equity ($M) | 710 |
| Market value ($M) | 8,180 |
| Enterprise value, market value plus net debt ($M) no debt reported | 7,612 |
| Enterprise value to sales (×) no debt reported | 8.0 |
| Enterprise value to operating income (×) no debt reported | 58.3 |
| Price to earnings (×) | 74.7 |
| Price to book value (×) | 11.5 |
| Free-cash-flow yield (%) | 2.4 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 4.4% of shares outstanding sold short, 6.8 days of average trading to cover, −0.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $78.6M |
| 12 monthsfrom | $0 | $122.2M |
Linked companies · as of
The thesis
Kiniksa Pharmaceuticals is modestly more likely than not to beat the S&P 500 over the next three months. The case rests on its third ARCALYST guidance raise of 2026, to $1.045–1.050 billion in net product revenue, announced on 27 October 2026. Fourth-quarter sales and the first 2027 range, due in the early-2027 results report, settle it.
ARCALYST treats recurrent pericarditis, a repeating inflammation of the sac around the heart, and is Kiniksa's only marketed drug. Third-quarter 2026 revenue was $286 million, up 58.1% from a year earlier, according to the 10-Q filed 27 October 2026. The operating margin widened to 19.0% in that quarter from 13.3% a year earlier.
The shares closed at $96.33 on 13 November 2026, close to MarketBeat's $100.57 consensus target of 9 November 2026. The price already carries the raised 2026 range, so further gains depend on what management signals about 2027. The first public comment since the report comes on 16 November 2026, at a fireside chat at the Jefferies Global Healthcare Conference in London.
Executive selling weighs on the case. Five officers sold stock between 30 October 2026 and 9 November 2026, all under Rule 10b5-1 pre-arranged plans, according to SEC Form 4 filings, and those filings show no insider purchase. The rating is Medium because sales momentum, rising margins and a debt-free balance sheet outweigh that supply, while a price near the consensus target limits the edge.
Bullish and bearish views on Kiniksa Pharmaceuticals International, plc
The bull case on Kiniksa Pharmaceuticals International, plc (KNSA), in brief: three guidance raises in one year. The bear case: the chief executive sold on five sessions.
Bull case
- Three guidance raises in one year. Kiniksa raised its 2026 ARCALYST range on 28 April 2026, 28 July 2026 and 27 October 2026, reaching $1.045–1.050 billion from $980–995 million at the last step. Benzinga reported on 27 October 2026 that the new range sat above a $996.1 million analyst estimate.
- Margins are widening with scale. Gross margin held at 90.3% for three straight quarters to 30 September 2026, and the operating margin reached 19.0% in the third quarter (10-Q filed 27 October 2026). Free cash flow was $197 million over the four quarters to 30 September 2026.
- Most eligible patients are untreated. About 23% of roughly 14,000 multiple-recurrence pericarditis patients were on ARCALYST at 30 September 2026, with more than 5,450 prescribers since launch and average therapy of about three years (Kiniksa third-quarter release, 27 October 2026).
- Brokers raised targets after the report. JPMorgan lifted its target to $122 on 30 October 2026; Wells Fargo moved to $110, Wedbush to $102 and Goldman Sachs to $101 on 28 October 2026 (Benzinga).
- The balance sheet carries no debt. Cash and short-term investments were $569 million at 30 September 2026 with no debt reported (10-Q filed 27 October 2026). That funds the KPL-387 Phase 3 trial without a share sale.
Bear case
- The chief executive sold on five sessions. Chairman and Chief Executive Sanj Patel sold 402,494 shares at an average of $92.92 from 30 October to 3 November 2026 and 151,300 at an average of $94.71 on 4 November 2026, after exercising options (SEC Form 4s filed 3 November 2026 and 6 November 2026).
- Selling spans the leadership team. The chief operating officer sold 103,585 shares, the chief medical officer 96,000 and the chief financial officer 36,783 between 30 October 2026 and 2 November 2026. The chief accounting officer sold 36,260 shares on 30 October 2026 and 11,280 at $98.54 on 9 November 2026 (SEC Form 4s filed 3 November 2026 and 12 November 2026).
- The multiples are full. At the 13 November 2026 close, on filed figures to 27 October 2026, the shares trade at 74.7 times earnings and 8.0 times sales. Kiniksa shares ARCALYST profits with licensor Regeneron, so only part of each revenue gain reaches its earnings.
- Share count is rising. Diluted shares rose 6.1% from a year earlier in the quarter to 30 September 2026 (10-Q filed 27 October 2026), which dilutes per-share growth.
- One product carries the company. Kiniksa expects Phase 3 PASTORALE data for KPL-387 in the second half of 2027 (third-quarter release, 27 October 2026), so ARCALYST alone drives results until then.
Price setup
The shares closed at $96.33 on 13 November 2026, 3.0% below the 52-week intraday high of $99.31 set on 9 November 2026. The close that day was $98.76. The shares then eased to $95.02 on 10 November 2026 and firmed to $96.28 and $96.33 over the following sessions.
The 3-month change is 21.7%, measured from the $79.18 close of 17 August 2026. As of 13 November 2026 the 50-day moving average was $82.18 and the 200-day $62.83, with the price well above both. The 52-week closing low was $37.92 on 15 January 2026.
The gain since the 27 October 2026 report is the part of the case the price tests. On report day the shares rose 23.1% intraday to $89.86 (Benzinga). Across US stocks, no reliable effect has been found so far in what follows a one-day jump of that size. Holding above the 50-day moving average keeps the post-report gain intact; the kill line sits just under that average.
Catalysts ahead
- 16 November 2026: Fireside chat at the Jefferies Global Healthcare Conference in London, 11:00 a.m. GMT. First public management comment since the 27 October 2026 report; any read on fourth-quarter demand or 2027 growth tests the raised 2026 range.
- ~31 December 2026 (est.): Company target for starting the KPL-1161 Phase 1 trial. Shows whether the pipeline behind ARCALYST and KPL-387 keeps to the timeline Kiniksa stated on 27 October 2026.
- ~11 January 2027 (est.): J.P. Morgan Healthcare Conference, where Kiniksa presented in January 2026. Typically the first public management read on full-year sales before the formal fourth-quarter report.
- ~24 February 2027 (est.): Fourth-quarter and full-year 2026 results with first 2027 ARCALYST guidance. Settles whether sales met the $1.045–1.050 billion 2026 range and sets the growth bar for 2027.
What would change the view
A weekly close below $80, under the 50-day moving average, which would erase most of the gain since the 27 October 2026 report. Fourth-quarter 2026 ARCALYST revenue below the implied $301 million floor, or first 2027 guidance below about $1.30 billion, would also break the case.
The risks this note tracks, each with what would confirm it:
- ARCALYST growth slows after three guidance raises in 2026. Confirmed by: fourth-quarter 2026 revenue below the implied $301 million floor, or first 2027 ARCALYST guidance below about $1.30 billion.
- Patient uptake plateaus among multiple-recurrence pericarditis patients. Confirmed by: penetration of the roughly 14,000 multiple-recurrence patients stalling near 23–25% for two quarters in company reports.
- A competitor shortens how long patients stay on IL-1 therapy. Confirmed by: positive Phase 3 MAVERIC results from Cardiol Therapeutics showing CardiolRx prevents recurrence after patients stop an IL-1 blocker.
- Executive selling keeps adding supply near the 52-week high. Confirmed by: new officer Form 4 sales or Form 144 notices in November or December 2026, especially sales outside Rule 10b5-1 plans.
- The price has reached the consensus target, leaving little room for a soft 2027 guide. Confirmed by: analysts holding targets near the $100.57 consensus after the 16 November 2026 Jefferies chat, or 2027 guidance implying growth well below 2026's pace.
- The KPL-387 timetable slips, extending dependence on one licensed product. Confirmed by: a company update moving PASTORALE Phase 3 data beyond the second half of 2027, or a safety or efficacy problem in the trial.
What it trades with
The largest recent moves came on Kiniksa's own reports. On 27 October 2026 the shares rose 23.1% intraday while the S&P 500 gained 0.5% (Benzinga), so the stock trades on ARCALYST sales and guidance more than on broad biotech sentiment. Regeneron (REGN) licensed ARCALYST to Kiniksa and shares in its profits, giving it an indirect link to the same sales line, though ARCALYST is a small part of Regeneron's business. Cardiol Therapeutics (CRDL) runs the Phase 3 MAVERIC trial of CardiolRx in recurrent pericarditis, enrolling patients whose IL-1 blocker is scheduled to stop (ClinicalTrials.gov NCT06708299, updated September 2026); its readout bears directly on how long patients stay on ARCALYST.
Caveats
- Kiniksa's guidance covers ARCALYST net product revenue only; total company revenue is a separate figure. Kiniksa third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Kiniksa licenses ARCALYST from Regeneron and shares profits on it, so net product revenue is not the same as profit retained by Kiniksa. Form 10-Q for the third quarter of 2026 · as of
- Kiniksa is a UK plc incorporated in England and Wales; its Class A ordinary shares trade on Nasdaq, and its other share classes are not publicly traded. Form 10-Q for the third quarter of 2026 · as of
- Kiniksa expects KPL-387 Phase 3 data in the second half of 2027 and patient access in 2028 or 2029; both dates are company expectations, not approvals. Kiniksa third-quarter 2026 results release (8-K exhibit 99.1) · as of
The evidence, claim by claim (8)
- Full-year 2026 ARCALYST net-product-revenue guidance rose to $1.045–1.050 billion from $980–995 million, the third raise of 2026. Kiniksa third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Third-quarter 2026 ARCALYST net product revenue was $286.0 million versus $180.9 million a year earlier; nine-month revenue was $743.8 million and third-quarter net income $47.3 million. Kiniksa third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Operating margin was 19.0% in the quarter to 30 September 2026 versus 13.3% a year earlier; free cash flow was $197 million over four quarters; cash and short-term investments $569 million with no debt. Form 10-Q for the third quarter of 2026 · as of
- About 23% of roughly 14,000 multiple-recurrence pericarditis patients were on ARCALYST, with more than 5,450 prescribers since launch and average therapy duration of about three years. Kiniksa third-quarter 2026 results release · as of
- CEO Sanj Patel sold 402,494 shares (average $92.92) from 30 October to 3 November 2026 and 151,300 shares (average $94.71) on 4 November 2026, all under a Rule 10b5-1 plan. SEC Form 4s filed 3 November 2026 and 6 November 2026 · as of
- Chief Accounting Officer Michael Megna exercised and sold 11,280 shares at $98.54 on 9 November 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 12 November 2026 · as of
- JPMorgan raised its Kiniksa price target to $122 with an Overweight rating; Wells Fargo had moved to $110, Wedbush to $102 and Goldman Sachs to $101 on 28 October 2026. Benzinga analyst reports, 28 October 2026 and 30 October 2026 · as of
- Kiniksa management will hold a fireside chat at the Jefferies Global Healthcare Conference in London on 16 November 2026 at 11:00 a.m. GMT, with a webcast. Kiniksa press release, 11 November 2026 · as of
Sources
- SEC EDGAR
- Kiniksa Pharmaceuticals International, plc - Form 4 · sec.gov
- Stock Titan
- Rallies ·
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High - What's Next? · marketbeat.com ·
- CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) · clinicaltrials.gov
Related · shared themes
AMGN
Amgen
Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing…
LQDA
Liquidia
Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third…
CRSP
CRISPR Therapeutics
CRISPR Therapeutics shares are more likely to lag the S&P 500 over three months: they hit a 52-week closing low of $42.62 on 12 November…
EWTX
Edgewise Therapeutics
Edgewise Therapeutics is modestly more likely than not to beat the S&P 500 over three months: FDA-cleared Phase 3 plans for heart drug…